Tuesday, November 29, 2011

FDA accepts Onyx application for multiple myeloma drug

Federal regulators accepted Onyx Pharmaceuticals Inc.’s application for approval of the South San Francisco company’s multiple myeloma drug.
It is an important step in the approval process for carfilzomib, which Onyx (NASDAQ: ONXX) obtained in its November 2009 acquisition of Proteolix Inc. Onyx in late September completed its application to the Food and Drug Administration.

No comments:

Post a Comment